<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01529749</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-IMMUNESARTAN</org_study_id>
    <secondary_id>2011-002071-42</secondary_id>
    <nct_id>NCT01529749</nct_id>
  </id_info>
  <brief_title>Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated</brief_title>
  <official_title>Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Felipe Garcia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a open controlled trial in which 48 HIV-1 patients successfully treated with
      EFV/FTC/TDF will be randomized to one of 4 groups in equal proportion between arms (1:1). The
      four arms are as follows:

      Arm I: EFV / FTC / TDF (n = 12) Arm II: EFV / FTC / TDF + LST (n = 12) Arm III: FTC / TDF +
      MK-0518 (n = 12) Arm IV: FTC / TDF + LST + MK-0518 (n = 12)

      The allocation will take place in two phases:

      Phase I: 24 patients 1:1 receiving EFV/FTC/TDF vs. EFV/FTC/TDF + Losartan

      If losartan arm shows benefits we will proceed to the second phase:

      Phase II: 24 patients 1:1 to receive FTC/TDF+ MK-0518 versus FTC/TDF + MK-0518 + losartan.

      Patients will be followed up during 12 months to determinate the proportion of patients with
      decreased collagen deposition in TL equal to or greater than 50%.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with 50% reduction of fibrosis in lymphatic tissue.</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with changes in the levels of IL-6, D-dimer and CRP in different groups.</measure>
    <time_frame>12, 24, 36 and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with increased CD4 in peripheral blood and in lymphatic tissue.</measure>
    <time_frame>peripheral blood: 12, 24, 36 and 48 weeks, Lymphatic tissue: week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with undetectable plasma viral load and decreased in lymphatic tissue in different groups</measure>
    <time_frame>VL in plasma: 12, 24, 36, 48 weeks, Lymphatic tissue: week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with changes in the CD4/CD8 ratio in peripheral blood in different groups.</measure>
    <time_frame>12, 24, 25 and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with reduced intima-media complex in carotid ultrasound in different groups.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with changes in levels of metalloproteinases and their inhibitors, beta2-microglobulin and CSF cells and proteins.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with improvement in neuropsychological test CDS</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and types of adverse events and laboratory abnormalities in the different groups.</measure>
    <time_frame>12, 24, 36 and 48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>EFV/FTC/TDF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>EFV/FTC/TDF + Losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FTC/TDF + MK-0518</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FTC/TDF+MK-0518+Losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EFV/FTC/TDF + Losartan</intervention_name>
    <description>EFV/FTC/TDF --&gt; oral, 600/200/245 mg, od Losartan --&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.</description>
    <arm_group_label>EFV/FTC/TDF + Losartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EFV/FTC/TDF</intervention_name>
    <description>600/200/245 mg, od, oral</description>
    <arm_group_label>EFV/FTC/TDF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FTC/TDF + MK-0518</intervention_name>
    <description>FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral</description>
    <arm_group_label>FTC/TDF + MK-0518</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FTC/TDF+MK-0518+Losartan</intervention_name>
    <description>FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral Losartan --&gt; -&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.</description>
    <arm_group_label>FTC/TDF+MK-0518+Losartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients older than 18 years.

          2. Patients with HIV infection in antiretroviral treatment with EFV / FTC / TDF with
             undetectable viral load (VL &lt;37 copies) for at least 48 weeks.

          3. Nadir CD4 +&gt; 250 cells/mm3.

          4. Patients, properly informed, give their written consent to participate in the study.

        Exclusion Criteria:

          1. Criteria for patients with AIDS.

          2. Patients with active opportunistic diseases.

          3. Patients coinfected with HCV.

          4. Patients without tonsillar tissue.

          5. Treatment with other drugs receptor antagonists or angiotensin II converting enzyme
             inhibitors, angiotensin II.

          6. Kidney failure.(Glomerular Filtration Rate (GFR &lt; 60 mL/mn)

          7. Severe liver failure (PT&gt; 60% ).

          8. Pregnant women

          9. Known hypersensitivity or contraindication to any study drug.

         10. determination of blood pressure (BP) &lt;100/60 mmHg

         11. Hyponatremia with serum Na numbers &lt;132 Meq / l

         12. History of chronic vomiting the last 6 months

         13. History of chronic diarrhea the last 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2012</study_first_submitted>
  <study_first_submitted_qc>February 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2012</study_first_posted>
  <last_update_submitted>February 18, 2016</last_update_submitted>
  <last_update_submitted_qc>February 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Felipe Garcia</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Neurocognitive Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 17, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

